SA
Sign upLog In

Kalvista Pharmaceuticals Inc (KALV)

SG&A Expenses

$198.25M

TTM · Period ending: · USD

KALV logo

KALV SG&A Expenses

Latest reported$198.25M
KALV TTM SG&A Expenses ($3.41M → $198.25M)
High-resolution chart · PNG

KALV sg&a expenses history

Trailing twelve months (TTM) · USD. Each value covers four complete reported quarters.

Kalvista Pharmaceuticals Inc SG&A Expenses — Trailing twelve months (TTM) (USD)
Period endingSG&A Expenses (USD)
198,251,000
178,779,000
160,685,000
143,369,000
116,287,000
100,355,000
80,430,000
61,886,000
54,071,000
38,641,000
35,102,000
32,251,000
30,595,000
30,416,000
30,479,000
28,730,000
26,447,000
25,014,000
21,629,000
19,205,000
16,636,000
13,767,000
13,275,000
13,062,000
13,031,000
12,782,000
12,614,000
11,803,000
10,927,000
9,837,000
9,066,000
9,160,000
8,862,000
9,109,000
12,006,000
11,383,000
11,390,000
10,729,000
7,020,000
6,313,000
5,403,000
4,866,000
4,343,000
4,460,000
3,981,000
3,412,000
2,986,000
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.